<DOC>
	<DOCNO>NCT00440245</DOCNO>
	<brief_summary>This study investigate potential difference two puff salbutamol protects airway smooth muscle contract people asthma chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Bronchoprotection Salbutamol Asthma Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>In asthma , administration ( inhalation ) selective β2 receptor agonist ( e.g . salbutamol ) , prior methacholine challenge show shift dose response curve right `` bronchoprotect '' airway airway smooth muscle contraction . The extent β2 receptor agonist bronchoprotection COPD unknown . Airway hyperresponsiveness ( AHR ) direct act agent histamine methacholine feature asthma COPD . In asthma , abnormality lead AHR believe due change airway smooth muscle ( e.g . hypertrophy , hyperplasia , contractile apparatus ) whereas COPD AHR likely due structural geometric change . The investigator hypothesize bronchoprotection afford salbutamol methacholine challenge great asthma COPD due difference underlie airway abnormality .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>asthma COPD asthma COPD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>